期刊
EXPERT OPINION ON DRUG DISCOVERY
卷 6, 期 2, 页码 195-203出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/17460441.2011.546395
关键词
brain metastasis; glioblastoma; motexafin gadolinium; radiation sensitizer; radiosurgery; whole brain radiation
Areas covered: This paper provides a clinical context by reviewing the background of radiosensitizers, followed by a review of the preclinical discovery of motexafin gadolinium and its clinical testing. We also highlight its most promising applications and comment on the reasons for the observed clinical outcomes. Expert opinion: Motexafin gadolinium is a novel radiosensitizer with clearly documented efficacy, particularly in patients with brain metastases. If this agent had been tested upfront in patients diagnosed with brain metastases from NSCLC who had not been delayed by the administration of systemic chemotherapy, it may have become part of the standard of care in this setting. Continued investigations using this agent are under way and remain promising.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据